Counterpoint Biomedica

Executive Summary

Counterpoint Biomedica is a preclinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to advancing oncology therapeutics and diagnostics through proprietary tumor-targeting platforms. Founded in 2019 by practicing oncologists and a research scientist, the company's core technology aims to enhance the efficacy and safety of FDA-approved chemotherapeutic and biological agents by equipping them with proactive tumor-targeting capabilities. This approach seeks to improve the therapeutic index of existing cancer drugs while potentially enabling more precise liquid biopsy applications. As a private entity with no disclosed funding rounds or valuation, Counterpoint operates in the early-stage biotech landscape, focusing on platform validation and potential partnering opportunities. The company's strategy revolves around differentiating its drug delivery platforms from conventional methods, which may position it for strategic collaborations with larger pharmaceutical firms seeking to enhance their oncology pipelines. However, given its preclinical status and limited publicly available data, the company faces typical early-stage risks including research setbacks, funding needs, and regulatory hurdles.

Upcoming Catalysts (preview)

• Q3 2026Lead candidate IND-enabling studies completion35% success
• TBDInitial proof-of-concept data from tumor-targeting platform50% success
• TBDStrategic partnership or licensing deal announcement25% success